Clinical trials: Solid Malignancies or Lymphomas
Hematological Neoplasms, Non-Hodgkin's Lymphoma
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension…
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma
- Trial name
- NCT02223052
- Testing
- CC-486, Vidaza
- Where
- 10 sites in United States
- Volunteers
- 89 people
- Sponsor
- Celgene
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Solid Tumor, Lymphoma
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Identification of T cell inhibitory signals, including PD-1/PD-L1, has prompted the development of a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance…
- Trial name
- NCT03991559
- Testing
- Manganese Chloride, Anti-PD-1 antibody, Systemic therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Brain Cancer, Cancer
A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images. Tumour growth rate is a useful indicator of tumour aggression and response to treatment.
- Conditions
- Brain Cancer, Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT01065805
- Testing
- 18F-FLT
- Where
- Canada
- Volunteers
- 94 people
- Sponsor
- AHS Cancer Control Alberta
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Lymphoma
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
This is a phase I, open-label, dose-escalation study of CUDC-427 in patients with advanced or refractory solid tumors or lymphoma.
- Trial name
- NCT01908413
- Testing
- CUDC-427
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Curis, Inc.
Solid Tumor and Lymphoma
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
This trial is an open, dose escalation phase I clinical study. Subjects can only enter this study after they meet the inclusion and exclusion criteria.Into subjects will accept HLX60 intravenous infusion, every 3 weeks, treatment…
- Trial name
- NCT05606380
- Testing
- HLX60
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Shanghai Henlius Biotech
Meningeal Neoplasms
DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor
The purpose of this study is to find out how well an experimental drug called DepoCyt works for neoplastic meningitis (cancer that has spread to the tissues around the brain and spinal cord).
- Trial name
- NCT00029523
- Testing
- Intrathecal (injected into the spinal fluid) DepoCyt, Intrathecal methotrexate, Intrathecal cytarabine (also known as ara-C)
- Where
- 23 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Solid Tumors or Lymphoma
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
This study is an open-label, multicenter, phase Ia/Ib study. The study will evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma…
- Trial name
- NCT05460767
- Testing
- IBI363, Bevacizumab
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumor, Central Nervous System Tumor
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.
- Conditions
- Solid Tumor, Central Nervous System Tumor, Lymphoma, Leukemia
- Trial name
- NCT02932280
- Testing
- Neratinib
- Where
- 9 sites in United States, Canada
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Lymphoma
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
This is an open label, dose escalation, phase I study of the combination of MLN9708 plus Nelfinavir.
- Trial name
- NCT03422874
- Testing
- MLN9708, Nelfinavir
- Where
- United States
- Sponsor
- Dartmouth-Hitchcock Medical Center
Anemia, Hodgkin Disease
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of once- weekly dosing of PROCRIT® (a glycoprotein that stimulates red blood cell production) versus placebo in the treatment of anemia in children with…
- Conditions
- Anemia, Hodgkin Disease, Leukemia, Lymphoma, Non-hodgkin
- Trial name
- NCT00261677
- Testing
- epoetin alfa
- Volunteers
- 224 people
- Sponsor
- Ortho Biotech Products, L.P.
Brain and Central Nervous System Tumors, Lymphoma
Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00006102
- Testing
- becatecarin
- Where
- 226 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma
- Trial name
- NCT00084695
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Cancer
Application of 68Ga-NODAGA-SNA006 Positron Emission Tomography/Computed Tomography (PET/CT) in Tumors
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the safety and clinical predictive value of 68Ga-NODAGA-SNA006 in subjects with solid tumor or lymphoma.
- Trial name
- NCT07059832
- Testing
- 68Ga-NODAGA-SNA006
- Where
- China
- Volunteers
- 30 people
- Sponsor
- First Hospital of China Medical University
Solid Tumors, Lymphoma
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
Background: Imetelstat is a cancer treatment drug that may slow or stop tumor growth. It may also prevent tumors from spreading to other parts of the body.
- Trial name
- NCT01568632
- Testing
- Imetelstat
- Sponsor
- National Cancer Institute (NCI)
Solid Tumours
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
This is an open-label, multi-center Phase I study conducted to define the recommended Phase 2 dose, toxicity profile, pharmacokinetics and biologically active dose range of GSK1059615.
- Trial name
- NCT00695448
- Testing
- GSK1059615
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Neoplasms, Lymphoma Neoplasms
A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies
The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659…
- Trial name
- NCT03338881
- Testing
- [14C]-TAK-659, TAK-659
- Sponsor
- Calithera Biosciences, Inc
Non-Hodgkin's Lymphoma, Solid Cancers
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
This is an open-label, Phase I, dose-escalation study using a 3 + 3 design to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered QD.
- Trial name
- NCT00876122
- Testing
- GDC-0941
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.